BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

IKT

Inhibikase Therapeutics, Inc.
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$0
$400000$200000$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$31M−59.9% year on year
$200M$100M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$43M
$20M$0−$20M−$40M−$60M
Q2 ’24Q4 ’24Q2 ’25Q4 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty